NCT06088433 - Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease | Biotech Hunter

Enrollment

292

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2025

Conditions

Coronary Heart Disease

Interventions

DRUG

Ticagrelor

Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)

DRUG

Clopidogrel

Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)

DRUG

Aspirin

Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)

Trial Locations (1)

Unknown

Fuwai Hospital, Beijing